Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2004-04-15 | Timothy J. Triche, M.D. has been the Chairman of the Department of Pathology and Laboratory Medicine at Childrens Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. |
| 2005-04-15 | Timothy J. Triche, M.D. has been the Chairman of the Department of Pathology and Laboratory Medicine at Childrens Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. |
| 2006-03-31 | Timothy J. Triche, M.D. has been the Chairman of the Department of Pathology and Laboratory Medicine at Childrens Hospital Los Angeles since 1988. Committee memberships: Audit Committee (Member), Compensation Committee (Chairman), Nominating and Corporate Governance Committee (Member). No specific annual compensation stated for Dr. Triche. |
| 2007-04-09 | Timothy J. Triche, M.D. has been the Chairman of the Department of Pathology and Laboratory Medicine at Childrens Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. He also serves on the Board of Directors of Novelix Pharmaceuticals, Inc., a private California-based biotechnology company and NanoValent Pharmaceuticals, Inc., a private nanotechnology company. |
| 2008-04-29 | Timothy J. Triche, M.D. has been the Chairman of the Department of Pathology and Laboratory Medicine at Childrens Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. He also serves on the Board of Directors of Novelix Pharmaceuticals, Inc., a private California-based biotechnology company and NanoValent Pharmaceuticals, Inc., a private nanotechnology company. |
| 2009-04-09 | Timothy J. Triche, M.D. has been the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. He also serves on the Board of Directors of Novelix Pharmaceuticals, Inc., a private California-based biotechnology company and NanoValent Pharmaceuticals, Inc., a private nanotechnology company. |
| 2010-04-22 | Dr. Triche has been the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. |
| 2011-04-29 | Dr. Triche has been the Director of the Center for Personalized Medicine at Children's Hospital Los Angeles since July 2010 and previously served as the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. |
| 2012-04-20 | Dr. Triche has been the Director of the Center for Personalized Medicine at Children's Hospital Los Angeles since July 2010 and previously served as the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. He also serves on the Board of Directors of Novelix Pharmaceuticals, Inc., a private California-based biotechnology company, NanoValent Pharmaceuticals, Inc., a private nanotechnology company, and WaferGen Biosystems, Inc., a publicly-traded biotechnology company developing molecular diagnostics technology and GenomeDx, a private Canadian biotechnology company developing prognostic tests for cancer. |
| 2013-04-19 | Dr. Triche has been the Director of the Center for Personalized Medicine at Children's Hospital Los Angeles since July 2010 and previously served as the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. He has also been a Professor of Pathology and Pediatrics at the University of Southern California Keck School of Medicine in Los Angeles, California since 1988. He also serves on the Board of Directors of Novelix Pharmaceuticals, Inc., a private California-based biotechnology company, NanoValent Pharmaceuticals, Inc., a private nanotechnology company, and WaferGen Biosystems, Inc., a publicly-traded biotechnology company developing molecular diagnostics technology, and GenomeDx, a private Canadian biotechnology company developing prognostic tests for cancer and Silicon Valley Biosystems, a private California-based biotechnology company. |
| 2014-04-28 | Dr. Triche has been the Director of the Center for Personalized Medicine at Children's Hospital Los Angeles since July 2010 and previously served as the Chairman of the Department of Pathology and Laboratory Medicine at Children's Hospital Los Angeles since 1988. Dr. Triche's prior service as an independent director of LTC Properties, Inc., current and past executive and director experience with other health care companies, and his overall background in the health care industry led the Board to conclude he should be nominated to serve another term as director. Director Compensation for the Year ended December 31, 2013: Timothy J. Triche Fees Earned or Paid in Cash $53,400 Stock Awards $97,734 Total $151,134. The Compensation Committee is responsible for overseeing, reviewing, and administering our compensation and benefit practices. The Board has determined that each member of the Compensation Committee is independent. Dr. Triche serves as Chairman of the Compensation Committee. |
| 2015-04-24 | Timothy J. Triche: Fees Earned or Paid in Cash $66,383, Stock Awards $84,105, Total $150,488. He serves on Compensation (Chairman) and Nominating and Corporate Governance Committees. |
| 2016-04-26 | Timothy J. Triche, MD is a member of the Audit and Nominating and Corporate Governance Committees and Chairman of the Compensation Committee. Director Compensation for the Year ended December 31, 2015: Timothy J. Triche received $70,000 in fees and $88,830 in stock awards, totaling $158,830. |
| 2017-04-26 | Timothy J. Triche, MD Director since 2000 Age 72 Dr. Triche has been the Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles since July 2010 ... Dr. Triche’s prior service as an independent director of LTC, current and past executive and director experience with other health care companies, and his overall background in the health care industry led the Board to conclude he should be nominated to serve another term as director. Director Compensation for the Year ended December 31, 2016 Timothy J. Triche $ 90,000 $ 130,823 $ 220,823 |
| 2018-04-24 | Timothy J. Triche Member of Audit Committee * Chairman of Compensation Committee * Member of Corporate Governance Committee; Director Compensation for the Year ended December 31, 2017: Timothy J. Triche Fees Earned or Paid in Cash $90,000 Stock Awards $90,012 Total $180,012 |
| 2019-04-23 | Timothy J. Triche, MD * C * Dr. Triche has been the Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles since July 2010. Director Compensation for the Year ended December 31, 2018 Timothy J. Triche $90,000 $90,008 $180,008 |
| 2020-04-21 | Timothy J. Triche * Chairman of Compensation Committee * Member of Nominating and Corporate Governance Committee. Director Compensation for the Year ended December 31, 2019: Timothy J. Triche Fees Earned or Paid in Cash $90,000 Stock Awards $95,000 Total $185,000. |
| 2021-04-20 | Timothy J. Triche, MD Director since 2000 Age 76 Dr. Triche has been the Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles since July 2010... Dr. Triche’s prior service as an independent director of LTC, current and past executive and director experience with other health care companies, and his overall background in the health care industry led the Board to conclude he should be nominated to serve another term as director. Committee memberships: Audit Committee member Chairman of Compensation Committee Director compensation for 2020: Cash fees earned: $90,000 Stock awards: $95,000 Total: $185,000 |
| 2022-04-19 | Timothy J. Triche, MD, Director since 2000, Age 77. Serves on Audit, Compensation, and Nominating and Corporate Governance Committees. Director compensation for 2021 was $188,750. |
| 2023-04-18 | Timothy J. Triche, MD Director since 2000 Age 78 Dr. Triche has been the Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles since July 2010 and previously served as the Chairman of the Department of Pathology and Laboratory Medicine at Children’s Hospital Los Angeles since 1988. ... The Board has five committees: (1) Audit; (2) Compensation; (3) Environmental, Social and Governance ("ESG"); (4) Investment and (5) Nominating and Corporate Governance. ... The Board has determined that each member of the Audit Committee is independent within the meaning of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and NYSE listing standards. ... The Board has determined that each member of the Compensation Committee is independent within the meaning of NYSE listing standards. Dr. Triche serves as Chairman of the Compensation Committee and served in that role throughout 2022. ... Director Compensation for the Year ended December 31, 2022 Name Fees Earned or Paid in Cash Stock Awards Total Timothy J. Triche $95,000 $95,000 $190,000 |
| 2024-04-16 | Timothy J. Triche, MD Director since 2000 Age: 79 Director, Center for Personalized Medicine, Children’s Hospital, Los Angeles Committee Memberships: Audit, Compensation, Nominating and Corporate Governance Director Compensation for the Year ended December 31, 2023: $190,000 |
Data sourced from SEC filings. Last updated: 2026-02-03